Derralynn Hughes

Prof.  Derralynn Hughes is Professor of Experimental Haematology at the University College London, Director of Clinical Pathway Groups and Clinical Director of Research and Innovation at the Royal Free London NHS Foundation Trust. She is co-clinical Director of the NCL cancer Alliance.

She has clinical responsibilities in the area of Haematology and Lysosomal Storage Disorders. She directs the research programme in the LSD unit where interests include understanding the pathophysiology of phenotypic heterogeneity in Fabry Disease and bone related pathology in Gaucher disease and malignancy. Prof Hughes is Principal Investigator of a number of clinical trials examining the efficacy of new agents in the treatment of Gaucher, Fabry, Pompe and MPS disorders. A particular interest relates to the clinical and biological effects of bone disease and malignancy in Gaucher disease and the effects of Fabry disease in women. She is an author of over 150 papers relating to macrophage biology and lysosomal Storage Disorders. Prof Hughes has a particular interest in service redesign methodology and how this can be systematically used to improve not only direct clinical care but also opportunities for public health interventions and research.